Aliko Scientific subsidiary Hospitex has won a public tender to supply cytology technology to the pathological anatomy department at the F Miulli Regional General Hospital in Italy.
The five-year contract involves the provision of Hospitex’s Cytofast liquid-based cytology (LBC) system and BLOCKfast Cell Block technology, enhancing the hospital’s ability to diagnose tumours with cytology solutions.
Go deeper with GlobalData
The integration of Hospitex’s technology is expected to bolster the department’s diagnostic precision, particularly for challenging samples from organs like the thyroid, bronchoalveolar lavages, breast tissue and lungs.
The contract, valued at €116,000 ($126,335), is projected to yield substantial recurring revenue over its duration due to ongoing reagent consumption.
The F Miulli Regional General Hospital specialises in the treatment of complex tumours.
The hospital adheres to the Puglia Region’s directives and houses the Oncology Orientation Center, which oversees the oncology network.
The centre’s approach promotes interdisciplinary collaboration and knowledge sharing to improve sustainable therapeutic options.
The hospital’s pathological anatomy department performs a spectrum of diagnostic tests, which encompass cytology, histology, and extemporaneous, immunohistochemical and molecular diagnostics.
Hospitex pursues advancements in digital pathology and plans to integrate its solutions with fluorescence in situ hybridisation (FISH) technology, aiming to refine diagnostic accuracy in pathology labs worldwide.
The company engages in in-house research, development, and manufacturing processes, which allows it to maintain stringent quality standards.
Hospitex’s advanced LBC technology is designed to process a wide range of cytological samples.
Last month, Hospitex secured a €300,000 contract for providing IT and networking systems for hospitals in Adwa, Ethiopia. This deal forms a part of a broader UNOPS-funded project.
